For many pharmaceutical companies, 2025 was a hard year to navigate. Would there be tariffs, and if so, how much? Would companies move manufacturing operations to the US? What was going to happen with Medicare drug price negotiations? What was their AI, direct-to-consumer, and digital strategy? Looking back on this wild year, leaders across pharma told Healthcare Brew it was one with regulatory uncertainty—but also one with plenty of innovation. Matt Wetzel, partner in Life Sciences regulatory and compliance, at Goodwin says, "In 2025, we watched the Trump administration use the full weight of the Oval Office—and not traditional regulatory approaches—to force drugmakers to reduce drug prices in the US and equalize prices around the globe. This was an untraditional but unmistakably effective use of the bully pulpit to move markets without moving statutes."
Read the Healthcare Brew article for more.